マーケットレポート詳細
リキッドバイオプシー（液体生検）の世界市場：2026年に至る臨床用途別、バイオマーカー別予測
Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-Cancer), End User (Reference Lab, Hospitals) - Global Forecast to 2026
- 出版元：MarketsandMarkets
出版元について - 発行年：2021年11月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文225ページになります。
- 商品コード：MAM2767
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
リキッドバイオプシー(液体生検)の世界市場規模は2021年で25億ドル、2026年に58億ドルに拡大すると予測されています。期間中の同市場の平均年成長率は18.1%で推移する見込みです。
リキッドバイオプシー(液体生検)市場の成長要因は、がんの発生率/有病率の上昇、非侵襲的治療手順への選好度の高まりなどが挙げられます。その一方で、特定のリキッドバイオプシーの感度が低いことが市場障壁となる可能性があります。
レポートはリキッドバイオプシー(液体生検)の世界市場について2026年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（製品/サービス別市場、循環バイオマーカー別市場、等）を中心に構成されています。また競合状況、主要企業情報（11社）、COVID-19によるリキッドバイオプシー(液体生検)市場への影響、価格分析などの分析も加味し、リキッドバイオプシー(液体生検)市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆リキッドバイオプシー(液体生検)の世界市場予測2019-2026年
・市場規模(US$)
◆製品/サービス別、市場-2026年
・アッセイキット
・器具
・サービス
※(市場規模US$)
◆循環バイオマーカー別、市場-2026年
・血中循環腫瘍細胞(CTC)
・無細胞腫瘍DNA(ctDNA)
・セルフリーDNA(cfDNA)
・細胞外小胞(EV)
・その他循環バイオマーカー
※(市場規模US$)
◆技術別、市場-2026年
・NGSを用いた他遺伝子並列解析
・PCRマイクロアレイを用いた単一遺伝子解析
※(市場規模US$)
◆用途別、市場-2026年
がん用途
・肺がん
・乳がん
・結腸直腸がん
・前立腺がん
・黒色腫
・その他がん
非がん用途
※(市場規模US$)
◆臨床用途別、市場-2026年
・治療法の選択
・治療モニタリング
・再発モニタリング
・早期がん検診
※(市場規模US$)
◆エンドユーザー別、市場-2026年
・リファレンスラボ
・病院/医師ラボラトリー
・学術/研究センター
・その他エンドユーズ
※(市場規模US$)
◆主要国地域別市場-2026年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
その他地域
※地域別に全セグメント別の細分化データ掲載、詳細は目次参照
※国別に各種セグメント別の細分化データ掲載
◆市場分析
・市場ダイナミクス（ドライバー、障壁、機会、課題）
・COVID-19によるリキッドバイオプシー(液体生検)市場への影響
・価格分析
・特許分析
・バリューチェーン分析
・ファイブフォース分析
・PESTEL分析
・市場シェア分析
・競合状況
◆リキッドバイオプシー(液体生検)の主要企業プロフィール動向
・QIAGEN N.V.
・F. HOFFMANN-LA ROCHE
・MYRIAD GENETICS, INC.
・THERMO FISHER SCIENTIFIC INC.
・GUARDANT HEALTH, INC.
・BIO-RAD LABORATORIES
・ILLUMINA, INC.
・EXACT SCIENCES
・SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
・BIOCEPT, INC.
・MDX HEALTH
（その他企業）
・NEOGENOMICS, INC.
・ANGLE PLC
・EPIGENOMICS AG
・MENARINI-SILICON BIOSYSTEMS
・VORTEX BIOSCIENCES, INC.
・EXOSOME DIAGNOSTICS, INC.
・MEDGENOME INC.
・AGENA BIOSCIENCE, INC.
・PERSONAL GENOME DIAGNOSTICS, INC.
・FREENOME HOLDINGS, INC.
・STRAND LIFE SCIENCES
・LUNGLIFE AI, INC.
・LUCENE HEALTH INC.
・ANPAC BIO-MEDICAL SCIENCE CO., LTD.
（全225頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1.... INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
・ FIGURE 1....................... LIQUID BIOPSY MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2.... RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
・ FIGURE 2.................. LIQUID BIOPSY MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 KEY DATA FROM SECONDARY SOURCES
2.2.2 PRIMARY DATA
2.2.2.1 PRIMARY SOURCES
2.2.2.2 KEY DATA FROM PRIMARY SOURCES
2.2.2.3 KEY INDUSTRY INSIGHTS
2.2.2.4 BREAKDOWN OF PRIMARY INTERVIEWS
・ FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LIQUID BIOPSY MARKET)
・ FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
・ FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 APPROACH 2: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
2.3.1.3 GROWTH FORECAST (2021-2026)
2.3.1.4 CAGR PROJECTIONS
・ FIGURE 6................. CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH.. 42
・ FIGURE 7............. LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
・ FIGURE 8.......................... DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET
2.9 GROWTH RATE ASSUMPTIONS
2.10 COVID-19 HEALTH ASSESSMENT
2.11 COVID-19 ECONOMIC ASSESSMENT
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
・ FIGURE 9................. CRITERIA IMPACTING THE GLOBAL ECONOMY
・ FIGURE 10........... RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET
3.... EXECUTIVE SUMMARY
・ FIGURE 11......... LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION)
・ FIGURE 12 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2021 VS. 2026 (USD MILLION)
・ FIGURE 13 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
・ FIGURE 14 LIQUID BIOPSY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
・ FIGURE 15....... LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2021 VS. 2026 (USD MILLION)
・ FIGURE 16... LIQUID BIOPSY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
・ FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4.... PREMIUM INSIGHTS
4.1 LIQUID BIOPSY MARKET OVERVIEW
・ FIGURE 18........ THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE LIQUID BIOPSY MARKET
4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
・ FIGURE 19. THE ASSAY KITS SEGMENT WILL CONTINUE TO DOMINATE
THE MARKET IN 2026
4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKERS, 2021 VS. 2026
・ FIGURE 20............ THE CIRCULATING TUMOR CELLS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
・ FIGURE 21.. MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.5 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2021 VS. 2026
・ FIGURE 22........ CANCER APPLICATIONS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2021 VS. 2026
・ FIGURE 23.......... THERAPY SELECTION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.7 LIQUID BIOPSY MARKET SHARE, BY END USER, 2021 VS. 2026
・ FIGURE 24.. REFERENCE LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.8 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・ FIGURE 25 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE LIQUID BIOPSY MARKET DURING THE FORECAST PERIOD
5.... MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 26........... LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 RISING INCIDENCE AND PREVALENCE OF CANCER
・ TABLE 1..... NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020,
BY TYPE OF CANCER
5.2.1.2 CANCER AWARENESS INITIATIVES UNDERTAKEN BY GLOBAL HEALTH ORGANIZATIONS
5.2.1.3 INCREASING PREFERENCE FOR NONINVASIVE TREATMENT PROCEDURES
5.2.2 RESTRAINTS
5.2.2.1 THE LOWER SENSITIVITY OF CERTAIN LIQUID BIOPSIES
5.2.3 OPPORTUNITIES
5.2.3.1 THE GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS
5.2.3.2 GROWTH OPPORTUNITIES IN EMERGING COUNTRIES
5.2.4 CHALLENGES
5.2.4.1 UNCLEAR REIMBURSEMENT SCENARIO
5.3 IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET
5.4 REALISTIC, PESSIMISTIC, AND OPTIMISTIC SCENARIOS
5.4.1 LIQUID BIOPSY MARKET
・ FIGURE 27.............................................. REALISTIC SCENARIO
・ FIGURE 28.......................................... PESSIMISTIC SCENARIO
・ FIGURE 29............................................ OPTIMISTIC SCENARIO
5.5 PRICING ANALYSIS
・ TABLE 2..................... PRICE OF LIQUID BIOPSY PRODUCTS (2021)
5.6 PATENT ANALYSIS
5.6.1 PATENT ANALYSIS OF CIRCULATING BIOMARKERS
5.7 VALUE CHAIN ANALYSIS
・ FIGURE 30 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
・ FIGURE 31. DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.8 ECOSYSTEM ANALYSIS OF THE LIQUID BIOPSY MARKET
・ FIGURE 32............ LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
5.9 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 3.. LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 DEGREE OF COMPETITION
5.10 REGULATORY LANDSCAPE
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 CANADA
5.10.2 EUROPE
5.10.3 ASIA PACIFIC
5.10.3.1 CHINA
5.10.3.2 JAPAN
5.10.4 LATIN AMERICA
5.10.4.1 BRAZIL
5.10.4.2 MEXICO
5.10.5 MIDDLE EAST
5.10.6 AFRICA
5.11 TECHNOLOGY ANALYSIS
5.12 PESTLE ANALYSIS
5.13 TRADE ANALYSIS
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.13.1.1 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016─2020 (USD MILLION)
5.13.1.2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016─2020 (TONS)
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
5.14.2 REVENUE SHIFT FOR THE LIQUID BIOPSY MARKET
6.... LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
・ TABLE 4............. LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
6.2 ASSAY KITS
6.2.1 REPEATED REQUIREMENT PURCHASES OF ASSAY KITS TO DRIVE THE GROWTH OF THIS SEGMENT
・ TABLE 5...................... KEY PRODUCTS IN THE ASSAY KITS MARKET
・ TABLE 6......... LIQUID BIOPSY MARKET FOR ASSAY KITS, BY REGION,
2019–2026 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH OF THIS SEGMENT
・ TABLE 7................. KEY PRODUCTS IN THE INSTRUMENTS MARKET
・ TABLE 8..... LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY REGION,
2019–2026 (USD MILLION)
6.4 SERVICES
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT THE MARKET GROWTH
・ TABLE 9........... LIQUID BIOPSY MARKET FOR SERVICES, BY REGION,
2019–2026 (USD MILLION)
7.... LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS
7.1 INTRODUCTION
7.1.1 PRIMARY NOTES
7.1.1.1 KEY INDUSTRY INSIGHTS
・ TABLE 10.. LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
7.2 CIRCULATING TUMOR CELLS (CTC)
7.2.1 BENEFITS OF EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF THE OVERALL TUMOR BURDEN TO DRIVE THE GROWTH OF THIS SEGMENT
・ TABLE 11. LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2019–2026 (USD MILLION)
7.3 CIRCULATING TUMOR DNA (CTDNA)
7.3.1 CTDNA ANALYSIS CAN SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS, THUS LEADING TO EARLY-STAGE DETECTION OF CANCER
・ TABLE 12 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION,
2019–2026 (USD MILLION)
7.4 CELL-FREE DNA (CFDNA)
7.4.1 APPLICATION OF CFDNA IN PRENATAL SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
・ TABLE 13.. LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION,
2019–2026 (USD MILLION)
7.5 EXTRACELLULAR VESICLES (EVS)
7.5.1 EVS ARE S・ TABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES, THUS ENSURING THE GROWTH OF THIS SEGMENT
・ TABLE 14 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION,
2019–2026 (USD MILLION)
7.6 OTHER CIRCULATING BIOMARKERS
・ TABLE 15........... LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2019–2026 (USD MILLION)
8.... LIQUID BIOPSY MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.1.1 PRIMARY NOTES
8.1.1.1 KEY INDUSTRY INSIGHTS
・ TABLE 16..... LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
8.2.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO DRIVE
THE GROWTH OF THIS SEGMENT
・ TABLE 17......... LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, 2019–2026 (USD MILLION)
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE THE GROWTH OF THIS SEGMENT
・ TABLE 18....... LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, 2019–2026 (USD MILLION). 96
9.... LIQUID BIOPSY MARKET, BY APPLICATION
9.1 INTRODUCTION
・ TABLE 19..... LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
9.2 CANCER APPLICATIONS
・ TABLE 20 CANCER INCIDENCE, BY REGION, 2020 VS. 2040 (MILLION)
・ TABLE 21... LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION,
2019–2026 (USD MILLION)
・ TABLE 22... LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2019–2026 (USD MILLION)
9.2.1 LUNG CANCER
9.2.1.1 INCREASING PREVALENCE OF LUNG CANCER TO PROPEL THE MARKET GROWTH
・ TABLE 23..... LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
・ TABLE 24... LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION)
9.2.2 BREAST CANCER
9.2.2.1 INCREASING GOVERNMENT FUNDING FOR BREAST CANCER RESEARCH IS EXPECTED TO DRIVE THE MARKET GROWTH
・ TABLE 25.. BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
・ TABLE 26 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION)
9.2.3 COLORECTAL CANCER.. 103
9.2.3.1 INCREASING PREVALENCE OF COLORECTAL CANCER TO PROPEL THE MARKET GROWTH
・ TABLE 27... COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
・ TABLE 28..... LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION,
2019–2026 (USD MILLION)
9.2.4 PROSTATE CANCER.. 105
9.2.4.1 GROWING NUMBER OF PROSTATE CANCER PATIENTS TO DRIVE THE GROWTH OF THIS MARKET
・ TABLE 29....... PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
・ TABLE 30......... LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION,
2019–2026 (USD MILLION)
9.2.5 MELANOMA
9.2.5.1 INCREASING NEED FOR THE EARLY DIAGNOSIS OF GENETICALLY MUTATED TUMORS TO DRIVE MARKET GROWTH
・ TABLE 31........ MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
・ TABLE 32....... LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION,
2019–2026 (USD MILLION)
9.2.6 OTHER CANCERS
・ TABLE 33.............................. GLOBAL CANCER INCIDENCE, 2020
・ TABLE 34 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION,
2019–2026 (USD MILLION)
9.3 NON-CANCER APPLICATIONS
9.3.1 APPLICATIONS OF LIQUID BIOPSY FOR NIPT AND ORGAN TRANSPLANTATION DIAGNOSIS DRIVES THE GROWTH OF THIS SEGMENT
・ TABLE 35 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
10.. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
10.1 INTRODUCTION
・ TABLE 36......... LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
10.2 THERAPY SELECTION
10.2.1 INCREASING PREFERENCE DUE TO NONINVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS SEGMENT
・ TABLE 37....... LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION,
2019–2026 (USD MILLION)
10.3 TREATMENT MONITORING
10.3.1 LIQUID BIOPSY FOR TREATMENT MONITORING QUANTITATIVELY CALCULATES THE CONCENTRATION OF CANCER-RELATED MUTATIONS
・ TABLE 38 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION,
2019–2026 (USD MILLION)
10.4 RECURRENCE MONITORING
10.4.1 THE ABILITY TO DETECT CANCER MUTATION THROUGH CTDNA IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
・ TABLE 39.. LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2019–2026 (USD MILLION)
10.5 EARLY CANCER SCREENING
10.5.1 POTENTIAL OF LIQUID BIOPSY IN THE DETECTION OF CANCER AT EARLY STAGES TO DRIVE MARKET GROWTH
・ TABLE 40.. LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2019–2026 (USD MILLION)
11.. LIQUID BIOPSY MARKET, BY END USER
11.1 INTRODUCTION
・ TABLE 41.. LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2 REFERENCE LABORATORIES
11.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES DRIVES THE GROWTH OF THIS SEGMENT
・ TABLE 42. LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
11.3 HOSPITALS AND PHYSICIAN LABORATORIES
11.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING THE GROWTH OF THIS SEGMENT
・ TABLE 43... LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES,
BY REGION, 2019–2026 (USD MILLION)
11.4 ACADEMIC & RESEARCH CENTERS
11.4.1 GROWING FOCUS OF RESEARCH IN THE DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
・ TABLE 44...... LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2019–2026 (USD MILLION)
11.5 OTHER END USERS
・ TABLE 45......... LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION,
2019–2026 (USD MILLION)
12.. LIQUID BIOPSY MARKET, BY REGION
12.1 INTRODUCTION
・ TABLE 46..... LIQUID BIOPSY MARKET, BY REGION, 2019–2026 (USD MILLION)
12.2 NORTH AMERICA
・ TABLE 47... NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020,
BY TYPE OF CANCER
・ FIGURE 33..... NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
・ TABLE 48... NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 49. NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 50................. NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
・ TABLE 51................. NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 52................. NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 53.... NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
・ TABLE 54.. NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION)
12.2.1 US
12.2.1.1 THE INCREASING PREVALENCE OF CANCER IS A KEY FACTOR EXPECTED TO DRIVE MARKET GROWTH IN THE US
・ TABLE 55...... US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 56................. US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 57 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 58 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
・ TABLE 59.... US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 60.... US: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.2.2 CANADA
12.2.2.1 THE AVAILABILITY OF VARIOUS CANCER SCREENING PROGRAMS IN CANADA IS EXPECTED TO DRIVE MARKET GROWTH IN CANADA
・ TABLE 61 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 62......... CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 63......... CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 64......... CANADA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 65............... CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 66............. CANADA: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION)
12.3 EUROPE
・ TABLE 67..... EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 68 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 69.......... EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 70......... EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 71......... EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 72............... EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 73............. EUROPE: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 INCREASING HEALTHCARE EXPENDITURE TO DRIVE THE MARKET GROWTH IN GERMANY
・ TABLE 74......... GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 75....... GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 76....... GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 77....... GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 78............. GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 79........... GERMANY: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION)
12.3.2 UK
12.3.2.1 INCREASING NUMBER OF DIAGNOSTIC LABORATORIES IN THE UK TO PROPEL THE MARKET GROWTH
・ TABLE 80...... UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 81................. UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 82 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 83 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
・ TABLE 84.... UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 85.... UK: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 RISING R&D EXPENDITURE IN FRANCE TO DRIVE THE MARKET GROWTH
・ TABLE 86 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 87.......... FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 88......... FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 89......... FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 90................ FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 91.... FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.4 REST OF EUROPE
・ TABLE 92..... ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 93............... ROE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 94..... ROE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 95..... ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
・ TABLE 96.. ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 97.. ROE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4 ASIA PACIFIC
・ FIGURE 34................... APAC: LIQUID BIOPSY MARKET SNAPSHOT
・ TABLE 98. APAC: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 99... APAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 100........... APAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 101........... APAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 102........... APAC: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 103................. APAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 104...... APAC: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.1 CHINA
12.4.1.1 GROWING PUBLIC ACCESS TO ADVANCED HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH IN CHINA
・ TABLE 105 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 106.......... CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 107.......... CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 108.......... CHINA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 109................ CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 110.... CHINA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.2 JAPAN
12.4.2.1 UNIVERSAL HEALTHCARE REIMBURSEMENT POLICY TO DRIVE THE MARKET GROWTH IN JAPAN
・ TABLE 111 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 112.......... JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 113.......... JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 114.......... JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 115................ JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 116.... JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.3 INDIA
12.4.3.1 INCREASING PRIVATE & PUBLIC INVESTMENTS IN THE COUNTRY’S HEALTHCARE SYSTEM IS EXPECTED TO DRIVE THE MARKET GROWTH
・ TABLE 117. INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 118........... INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 119........... INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 120........... INDIA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 121................. INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 122..... INDIA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.4 REST OF ASIA PACIFIC
・ TABLE 123.......... ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 124........ ROAPAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 125....... ROAPAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
・ TABLE 126....... ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 127............. ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 128........... ROAPAC: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION)
12.5 REST OF THE WORLD
・ TABLE 129.. ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)
・ TABLE 130............ ROW: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION)
・ TABLE 131.. ROW: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 132.. ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
・ TABLE 133 ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION)
・ TABLE 134 ROW: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
13.. COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN
THE LIQUID BIOPSY MARKET
・ TABLE 135.... OVERVIEW OF STRATEGIES DEPLOYED BY SOME LIQUID BIOPSY PRODUCT MANUFACTURING COMPANIES
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
・ FIGURE 35........ REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN
THE LIQUID BIOPSY MARKET
13.4 MARKET SHARE ANALYSIS
・ FIGURE 36... LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2020)
・ TABLE 136........ LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
13.5 COMPANY EVALUATION QUADRANT
13.5.1 LIST OF EVALUATED VENDORS
13.5.2 STARS
13.5.3 EMERGING LEADERS
13.5.4 PERVASIVE PLAYERS
13.5.5 PARTICIPANTS
・ FIGURE 37....... LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
13.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
13.6.1 PROGRESSIVE COMPANIES
13.6.2 STARTING BLOCKS.. 167
13.6.3 RESPONSIVE COMPANIES
13.6.4 DYNAMIC COMPANIES.. 167
・ FIGURE 38....... LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
13.7 COMPETITIVE BENCHMARKING
・ FIGURE 39.... PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE LIQUID BIOPSY MARKET
・ TABLE 137......................... COMPANY PRODUCT TYPE FOOTPRINT
・ TABLE 138........................ COMPANY GEOGRAPHICAL FOOTPRINT
13.8 COMPETITIVE SCENARIO.. 170
13.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS
・ TABLE 139 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
13.8.2 DEALS
・ TABLE 140............................................................ KEY DEALS
13.8.3 LIQUID BIOPSY: OTHER DEVELOPMENTS
・ TABLE 141...................................... OTHER KEY DEVELOPMENTS
14.. COMPANY PROFILES
14.1 KEY PLAYERS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS))*
14.1.1 QIAGEN N.V.
・ TABLE 142............................. QIAGEN N.V.: BUSINESS OVERVIEW
・ FIGURE 40.................. QIAGEN N.V.: COMPANY SNAPSHOT (2020)
14.1.2 F. HOFFMANN-LA ROCHE
・ TABLE 143............ F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
・ FIGURE 41...... F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
14.1.3 MYRIAD GENETICS, INC.
・ TABLE 144.............. MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
・ FIGURE 42... MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
14.1.4 THERMO FISHER SCIENTIFIC INC.
・ TABLE 145.. THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
・ FIGURE 43. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
14.1.5 GUARDANT HEALTH, INC.
・ TABLE 146............. GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
・ FIGURE 44.. GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2020)
14.1.6 BIO-RAD LABORATORIES
・ TABLE 147...... BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
・ FIGURE 45.. BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
14.1.7 ILLUMINA, INC.
・ TABLE 148......................... ILLUMINA, INC.: BUSINESS OVERVIEW
・ FIGURE 46...................... ILLUMINA: COMPANY SNAPSHOT (2020)
14.1.8 EXACT SCIENCES
・ TABLE 149....................... EXACT SCIENCES: BUSINESS OVERVIEW
・ FIGURE 47............ EXACT SCIENCES: COMPANY SNAPSHOT (2020)
14.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
・ TABLE 150..................... SYSMEX INOSTICS: BUSINESS OVERVIEW
・ FIGURE 48.... SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
14.1.10 BIOCEPT, INC.
・ TABLE 151........................... BIOCEPT, INC.: BUSINESS OVERVIEW
・ FIGURE 49................ BIOCEPT, INC.: COMPANY SNAPSHOT (2020)
14.1.11 MDX HEALTH
・ TABLE 152............................ MDX HEALTH: BUSINESS OVERVIEW
・ FIGURE 50.................. MDX HEALTH: COMPANY SNAPSHOT (2020)
14.2 OTHER PLAYERS
14.2.1 NEOGENOMICS, INC. 209
14.2.2 ANGLE PLC
14.2.3 EPIGENOMICS AG
14.2.4 MENARINI-SILICON BIOSYSTEMS
14.2.5 VORTEX BIOSCIENCES, INC.
14.2.6 EXOSOME DIAGNOSTICS, INC.
14.2.7 MEDGENOME INC.
14.2.8 AGENA BIOSCIENCE, INC.
14.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
14.2.10 FREENOME HOLDINGS, INC.
14.2.11 STRAND LIFE SCIENCES
14.2.12 LUNGLIFE AI, INC.
14.2.13 LUCENE HEALTH INC.
14.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS) MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
15.. APPENDIX